Cancer Detection And Classification Technology Articles & Analysis
5 articles found
Summary OTraces in collaboration with the Gertsen Institute in Moscow performed a blinded validation study on OTraces breast cancer detection products, the CDx Chemistry System for processing automated tests for detection of cancer; BC Sera Dx Immunochemistry test kit for the measurements of proteins that are predictive as a group of the presence on breast cancer in women; and the OTraces Cancer ...
VisionGate’s Non-Intrusive Testing, Patented Cell-CT Imaging and AI-Powered Cancer Detection Work Together to Deliver Early Detection of Lung Cancer. VisionGate’s mission is backed by cutting-edge technology that is designed to save lives through early detection and prevention of lung cancer. VisionGate’s breakthrough technologies include non-intrusive testing, 3D cell imaging ...
VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test. VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site ...
Summary OTraces, in collaboration with the Johns Hopkins Medical Center, Brady Urology Institute (JHMC), performed a blinded validation study on OTraces prostate cancer (PCa) detection products. The blinded validation project involves two phases, and the first has been completed: Phase I: Blinded third party validation of the test for men with aggressive PCa, Gleason score of 7(4+3), 8, 9, and ...
A fibre-optic probe can detect errant cancer cells within healthy tissue during brain tumour surgery with close to 100 per cent accuracy and sensitivity, reducing the risk of recurrence and thereby increasing a patient’s survival time, say the Canadian researchers who developed the device. The hand-held, pen-like instrument, known as a Raman spectroscopy probe, is able to differentiate ...
